FDA Extends Review of Rocket Pharma's Proposed Kresladi
By Colin Kellaher
Rocket Pharmaceuticals on Tuesday said the U.S. Food and Drug Administration has extended its review of the biotechnology company's application seeking approval of its proposed treatment of a rare pediatric immunodeficiency disorder.
Rocket said the FDA extended its target action date for a decision on marnetegragene autotemcel in severe leukocyte adhesion deficiency-I to June 30 from March 31 after the Cranbury, N.J., company submitted clarifying chemistry, manufacturing and controls) information in response to requests from the agency.
Rocket said the FDA confirmed that it won't hold an advisory committee meeting on the application for marnetegragene autotemcel, which the company plans to market as Kresladi.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 13, 2024 07:41 ET (12:41 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks